Trial Profile
Combination treatment with ipilimumab and immunoembolization in metastatic uveal melanoma
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 17 Jul 2015
Price :
$35
*
At a glance
- Drugs Ipilimumab (Primary) ; Granulocyte macrophage colony stimulating factor; Interleukin-2
- Indications Uveal melanoma
- Focus Adverse reactions; Therapeutic Use
- 17 Jul 2015 New trial record
- 02 Jun 2015 Results presented at the 51st Annual Meeting of the American Society of Clinical Oncology.